Serum Institute will have a capacity to make over 2.5 billion doses of vaccines a year as it is currently upscaling the capacity from over 1.6 billion doses  

Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of \"cutting corners\", said Thomas Cueni, director-general of the IFPMA

After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon

New vaccines are rarely certified for efficacy above 90 per cent. Their efficacy improves as millions are vaccinated over decades. In fact, most vaccines get certified in the 40-60 per cent efficacy band

The company could be looking at manufacturing 100 million doses to begin with, as per Chairman Pankaj Patel.

In stark contrast to the mayhem around the world, India's top three candidates - Serum-Oxford, Bharat Biotech and Zydus Cadila continued their scientific pursuits unobtrusively (the fourth, DRL-Gamaleya, just started India trials). At least 16 more vaccines are under development at home

The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research

A blow-by-blow account of how Indian vaccines are being readied

Sensex climbed 302 points to 44,825 and Nifty gained 90 points to 13,145

Brent crude rose 51 cents, or 1.1%, to $46.57 a barrel by 1322 GMT and hit a session high of $46.72, its highest since March 6. U.S. West Texas Intermediate crude gained 63 cents, or 1.5%, to $43.69

The announcement that comes a day after Oxford-Astrazeneca announced a similar level of efficacy for its COVID-19 vaccine allows India to hope for two vaccines to fight the COVID-19 pandemic in the country

Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first

Centre is worried about the caseload surge in urban centres, which has resulted in the enforcement of measures such as curfews by state governments.

The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine

The Prime Minister is expected to hold two back-to-back meetings, one with those states with high caseloads and another related to vaccine distribution strategy.

Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh

The participant was admitted to a hospital with viral pneumonitis, few days after being given the vaccine. He was discharged after a week.

\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19

Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week

Pfizer that its EUA submission is supported by solicited safety data from a randomised subset of approximately 8,000 participants aged 18 years or above and unsolicited safety data from approximately 38,000 trial participants